Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Equity-to-Asset : -1.15 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Brainstorm Cell Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Brainstorm Cell Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-4.86 Mil. Brainstorm Cell Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $4.21 Mil.

The historical rank and industry rank for Brainstorm Cell Therapeutics's Equity-to-Asset or its related term are showing as below:

BCLI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.87 Med: 0.59 Max: 0.92
Current: -1.15

During the past 13 years, the highest Equity to Asset Ratio of Brainstorm Cell Therapeutics was 0.92. The lowest was -1.87. And the median was 0.59.

BCLI's Equity-to-Asset is ranked worse than
92.27% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs BCLI: -1.15

Brainstorm Cell Therapeutics Equity-to-Asset Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Equity-to-Asset Chart

Brainstorm Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-1.87

0.69

0.66

-0.36

-1.15

Brainstorm Cell Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															-0.36	-0.62	-0.68	-0.45	-1.15

Competitive Comparison of Brainstorm Cell Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Equity-to-Asset falls into.

Brainstorm Cell Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Brainstorm Cell Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-4.858	/	4.208
	=

Brainstorm Cell Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-4.858	/	4.208
	=

Brainstorm Cell Therapeutics (NAS:BCLI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Brainstorm Cell Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (NAS:BCLI) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

GHDN:Germany GHDN:Germany

Address

1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019

Website

https://www.brainstorm-cell.com

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Executives

Stacy Lindborg	officer: EVP, Head Global Clin Research	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Nir Naor	director	BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Kirk Taylor	officer: Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Menghisteab Bairu	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Alla Patlis	officer: See Remarks	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Anthony Waclawski	officer: See Remarks	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Chaim Lebovits	officer: Chief Executive Officer	110 EAST 59TH STREET, NEW YORK NY 10019
David Setboun	officer: EVP and COO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Acc International Holdings Ltd.	other: Member of 10% owner group	MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110
Sankesh Abbhi	director	3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134
Jacob A Frenkel	director	188 E. 70TH ST., #29A, NEW YORK NY 10021
Arturo Araya	officer: Chief Commercial Officer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Preetam Shah	officer: EVP, CFO and Treasurer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Ralph Dr. Kern	officer: COO and Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Irit Arbel	director	6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000